Alecensa
FDA Approves Alecensa as Adjuvant Treatment for ALK-Positive NSCLC
The FDA approved alectinib (Alecensa, Genentech) for adjuvant treatment following tumor resection in patients with ...
APRIL 22, 2024
FDA Approves Alecensa for NSCLC
The FDA approved a new indication for Genentech's Alecensa, to treat people with anaplastic lymphoma kinase ...
NOVEMBER 7, 2017
Head-to-Head Trial Finds PFS Varies Between TKIs in NSCLC
In patients with ALK-positive NSCLC, the TKI alectinib increases PFS by a year or more relative to crizotinib, ...
JUNE 1, 2017
Load more